Dermatology

Official Title

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients with Severe or Very Severe Alopecia Areata BRAVE-AA1

Purpose

The purpose of this study is to evaluate the efficacy of baricitinib.

Could this study be right for you?

• Subject must self-identify as Black or African American 
• Subject's current episode of alopecia areata must be more than 6 months and no longer than 8 years
• Subject must not have any spontaneous improvement 
• Subject must be in good general health with no history of tuberculosis, heart disease, cancer, HIV, hepatitis B or C, or blood clots 
• Female subjects must not be pregnant, breastfeeding, or considering becoming pregnant for the duration of the study 

Age Range

18 years and up

Official Title

A Phase 3, Randomized, 24-week, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult
Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)

Purpose

The purpose of this study is to evaluate the efficacy of rocatinlimab. 

Could this study be right for you?

• Subject must have a diagnosis of atopic dermatitis for a least 6 months prior to study visit
• Subject must have tried a topical medication with little to no improvement
• Subject must be in good general health with no history of tuberculosis, heart disease, cancer, HIV, hepatitis B or C, or blood clots 
• Female subjects must not be pregnant, breastfeeding, or considering becoming pregnant for the duration of the study 

Age Range

18 years and up

Official Title

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa

Purpose

The purpose of this study is to evaluate the efficacy of povorcitinib.

Could this study be right for you?

• Subject must have a diagnosis of hidradenitis suppurativa for at least 3 months prior to study visit 
• Subject must have at least 5 active HS spots in 2 different body areas 
• Subject must have tried an oral or injected medication for HS with little to no improvement 
• Subject must be in good general health with no history of tuberculosis, heart disease, cancer, HIV, hepatitis B or C, or blood clots 
• Female subjects must not be pregnant, breastfeeding, or considering becoming pregnant for the duration of the study 

Age Range

18 years and up

Official Title

M16-047: A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Combination with Topical Corticosteroids on Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis

Purpose

The purpose of this study is to compare the effectiveness and safety of Upadacitinib (ABT-494) to placebo (pill without any active substance that looks like upadacitinib) in combination with topical corticosteroids for adolescents (12-17 years of age) and adults (18-75 years of age with moderate to severe atopic dermatitis (AD).

Could this study be right for you?

- Adolescent subjects must weigh more than 40 kg (88 lb) - Subject must be in good general health (other than Atopic Dermatitis) - Subject must have chronic Atopic Dermatitis (AD) with onset of symptoms at least 3 years before first dose of study medication - Subject must have documented history of inadequate response to topical corticosteroids (TCS), topical calcineurin inhibitor (TCI), or systemic treatment for AD within 6 months prior to first dose of study medication - Female subjects must not be pregnant, breastfeeding, or considering becoming pregnant for the duration of the study and for 30 days after last dose of the study drug. - No history of drug or alcohol abuse in the 6 months prior to receiving the first dose of study medication

Age Range

12 and up